We speculate that inhibition of STAT3 activation and reprogramming of STAT3‐regulated metabolic pathways are the predominant mechanisms associated with the in vitro and in vivo effect and efficacy of HJC0152 against NSCLC. Here, STAT3 is linked to non-small cell lung carcinoma.